-
-
News/HuiGene completed hundreds of millions of C rounds of financing, accelerating the pace of in vivo gene editing innovative drugs
On May 12, 2022, China's first self-developed CRISPR-Cas13 gene editing tool company HuiGene Therapeutics (Shanghai) ( referred to as "HuiGene") announced the completion of hundreds of millions of yuan in Series C financing.
Learn More
-
Gene Editing Platform
The Platform is designed to develop and optimize CRSPR/Cas-based RNA editing tools for treatment of disease. HuiGene boasts the R&D experience in CRISPR/Cas gene editing tools, and has developed smaller, more efficient and more specific RNA editing systems for the treatment of various diseases.Learn More -
Delivery Vector Platform
The Platform enables HuiGene to develop multiple safer AAVs with low immunogenicity and high tissue specificity for different diseases through high throughput screening, local modification and other means.Learn More -
Animal Model Platform
Relying on its advanced gene editing technologies and the world’s leading team, HuiGene can effectively construct various transgenic mouse models. Boosting its complete inspection and research devices, and systematic laboratory animal inspection techniques and practices, HuiGene has successfully induced and applied various animal models of common ophthalmic and neurological diseases etc. in pharmacodynamics research of new drugs for the diseases.Learn More -
Process Development Platform
The Platform deals with transformation of drugs from R&D to production. The developed processes for plasmids and AAV can obtain target products with desirable yield and quality, and is compliant, scalable and robust.Learn More
